Takeda Continues To Shed Pipeline Assets In Roivant Deal

07 Jun 2016

Takeda has set up a new company with Roivant to expedite the development of relugolix, an oral GnRH antagonist, for indications including prostate cancer and endometriosis.

In a move that marks a continued shedding of selected non-core assets, Takeda Pharmaceutical Co. Ltd. has set up with partner Roivant Sciences Ltd. a new company to develop a late clinical stage molecule that has shown potential in both oncology and women's health indications.

Myovant Sciences has been established based on the granting to it of an exclusive worldwide license - excluding commercial rights...